Department of Orthopaedic Oncology, MD Anderson Cancer Center, Houston, TX, 77030, USA.
Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, 77030, USA.
Curr Oncol Rep. 2018 Mar 26;20(5):37. doi: 10.1007/s11912-018-0668-z.
Mesenchymal chondrosarcoma is a rare but deadly form of chondrosarcoma that typically affects adolescents and young adults. While curative intent is possible for patients with localized disease, few options exist for patients in the unresectable/metastatic setting. Thus, it is imperative to understand the fusion-driven biology of this rare malignant neoplasm so as to lead to the future development of better therapeutics for this disease. This manuscript will briefly review the clinical and pathologic features of mesenchymal chondrosarcoma followed by an appraisal of existing data linked to the fusions, HEY1-NCOA2 and IRF2BP2-CDX1, and the associated downstream pathways.
间叶性软骨肉瘤是一种罕见但致命的软骨肉瘤,通常发生在青少年和年轻成年人中。虽然对于局限性疾病的患者可能有治愈的意图,但对于不可切除/转移性疾病的患者,几乎没有选择。因此,了解这种罕见的恶性肿瘤的融合驱动生物学至关重要,以便为这种疾病开发更好的治疗方法。本文将简要回顾间叶性软骨肉瘤的临床和病理特征,然后评估与融合、HEY1-NCOA2 和 IRF2BP2-CDX1 以及相关下游途径相关的现有数据。